Abstract
Purpose
In the ATTRACTION-2 trial, nivolumab significantly improved the survival of advanced gastric cancer patients. The pretreatment neutrophil-to-lymphocyte ratio (NLR) is prognostic in patients receiving immune checkpoint inhibitors (ICIs) to treat various cancers. However, a few reports have explored the relationships between NLR changes during ICI treatment and patient survival. Here, we evaluated factors (including NLR changes in patients on nivolumab monotherapy) prognostic for gastric cancer patients.
Methods
We retrospectively analyzed 98 gastric cancer patients who received nivolumab (3 mg/kg or 240 mg/body bi-weekly) at our institution between December 2014 and September 2018. We evaluated pretreatment data, and those obtained 30 and 60 days after treatment commenced. We explored the prognostic utility of relative NLR changes in terms of the overall survival (OS) of patients on nivolumab monotherapy.
Results
Over a median of 4.9 months of follow-up, 98 gastric cancer patients received a median of four treatment courses. The overall response and disease-control rates were 25% and 52%, respectively. The median OS was 6.4 months (95% confidence interval [CI] 4.6–9.1). On multivariate analysis, factors poorly prognostic in terms of OS were an ECOG performance status of 0–1, a pretreatment NLR > 3, and an NLR difference ≧ 2 over the 60 days before and after nivolumab administration (∆NLR60). Patients with ∆NLR60 values < 2 survived significantly longer than did those with ∆NLR60 values ≧ 2 (median OS 9.2 months [95% CI 6.4–11.6] vs. 4.0 months [2.1–4.9]; P = 0.0002).
Conclusions
Nivolumab monotherapy was efficacious in gastric cancer patients. NLR changes during such therapy may be predictive of outcomes.
Similar content being viewed by others
Abbreviations
- ICI:
-
Immune checkpoint inhibitor
- NLR:
-
Neutrophil-to-lymphocyte ratio
- irAE:
-
Immune-related adverse event
- CI:
-
Confidence interval
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9(3):215–221
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15(11):1224–1235
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 15(23):7412–7420
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372(4):320–330
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 33(18):2004–2012
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372(21):2018–2028
Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S et al (2016) Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 17(9):1283–1294
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR et al (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 33(13):1430–1437
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 30(1):44–56
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17(6):717–726
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM et al (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 6(1):74
Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D et al (2017) Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBioMedicine. 18:56–61
Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M et al (2018) Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study. Clin Lung Cancer. 20:208–214
Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D et al (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 112(12):1904–1910
Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 11:955–965
Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM et al (2018) Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 6(1):5
Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S et al (2018) Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE 13(10):e0197743
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228–247
Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 33(31):3541–3543
Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M et al (2018) Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget. 9(77):34520–34527
Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K (2010) Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer 13(4):212–221
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444
Granja S, Tavares-Valente D, Queirós O, Baltazar F (2017) Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol. 43:17–34
Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW et al (2017) Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer 20(2):254–262
Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ et al (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56(6):782–789
Middleton K, Jones J, Lwin Z, Coward JI (2014) Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 89(1):129–139
Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA et al (2017) Tumor response dynamics of advanced non-small cell lung cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin Cancer Res. 23(19):5737–5744
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18(3):e143–e152
Acknowledgements
We thank all participating patients, and our colleagues who advised us on study design, data analysis, and manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No author has any conflict of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ota, Y., Takahari, D., Suzuki, T. et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol 85, 265–272 (2020). https://doi.org/10.1007/s00280-019-04023-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-019-04023-w